CCTA continues to grow more and more important in the day-to-day treatment of heart patients. Hospitals and health systems that fail to embrace the modality risk falling behind.

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

The acquisition helps Teleflex expand its interventional and vascular portfolios. Biotronik, meanwhile, is shifting its focus toward implantable devices and digital healthcare. 

Kestra Medical Technologies, known for its wearable heart monitors and defibrillators, intends to sell 10 million common shares priced somewhere between $14 and $16 per share. 

CMS is expected to release a proposed national coverage determination decision memo by July.
 

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Other procedures are associated with higher profits—heart transplants, for instance—but CABG and TAVR are performed much more often.

The FDA recently cleared the company's cable-free, credit card-sized heart monitor that produces 12-lead ECGs.